(Q45879327)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Paul Knöbl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

M E Gorczyca

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

S C Nair

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

B Jilma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

S Priya

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

S Reitter

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

J C Gilbert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

R G Schaub

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Dockal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

K E McGinness

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

I Pabinger

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Srivastava

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Haemostasis

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1581-1590

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632032%20AND%20SRC:MED&resulttype=core&format=json

Social participation of patients with hemophilia in the Netherlands.

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Haemophilia care then, now and in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Barriers to compliance with prophylaxis therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

A survey of adherence to haemophilia therapy in six European countries: results and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Extending half-life in coagulation factors: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Management of acquired haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

The role of tissue factor and factor VIIa in hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Discovery and development of therapeutic aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Nanotechnology and aptamers: applications in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Tissue factor pathway inhibitor: structure-function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Citrate anticoagulation and the dynamics of thrombin generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Standardization of thromboelastography: a report from the TEG-ROTEM working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X

Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04790.X